In vitro comparison of cilofungin alone and in combination with other antifungal agents against clinical isolates of Candida species

Eur J Clin Microbiol Infect Dis. 1991 Jul;10(7):588-92. doi: 10.1007/BF01967280.

Abstract

Cilofungin, a lipopeptide antifungal agent, was tested for in vitro activity alone and in combination with ketoconazole, itraconazole, flucytosine and amphotericin B against 102 clinical isolates of Candida species. At 48 hours all isolates of Candida albicans, Candida tropicalis, Candida paratropicalis and Candida glabrata were inhibited by less than or equal to 5 meg/ml of cilofungin. In contrast, the MIC90 for Candida krusei was 10 mcg/ml and for Candida parapsilosis greater than 40 mcg/ml. The interaction of combinations of cilofungin with amphotericin B, itraconazole, ketoconazole and flucytosine was additive or indifferent at 48 hours for 100%, 88%, 78% and 70% of all Candida species isolates, respectively. Overall, cilofungin demonstrated good activity in vitro against most Candida species isolates.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amphotericin B / administration & dosage
  • Amphotericin B / pharmacology
  • Antifungal Agents / administration & dosage
  • Antifungal Agents / pharmacology*
  • Candida / drug effects*
  • Candida albicans / drug effects
  • Drug Therapy, Combination
  • Echinocandins
  • Flucytosine / administration & dosage
  • Flucytosine / pharmacology
  • Itraconazole
  • Ketoconazole / administration & dosage
  • Ketoconazole / analogs & derivatives
  • Ketoconazole / pharmacology
  • Microbial Sensitivity Tests
  • Peptides / administration & dosage
  • Peptides / pharmacology
  • Peptides, Cyclic*

Substances

  • Antifungal Agents
  • Echinocandins
  • Peptides
  • Peptides, Cyclic
  • Itraconazole
  • Amphotericin B
  • cilofungin
  • Flucytosine
  • Ketoconazole